Close Menu

NEW YORK – Avacta said Wednesday it has entered a collaboration with Cytiva to develop and manufacture a point-of-care rapid test to screen large populations for SARS-CoV-2, the coronavirus that causes COVID-19.

The test, using Affimer reagents developed by Wetherby, UK-based Avacta, is being designed to rapidly diagnose infection using a respiratory sample, such as saliva, the company said.

Cytiva, formerly GE Healthcare Life Sciences and now part of Danaher, will transfer the diagnostic assay to its point-of-care test-strip platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.